ayead retweeted
الإجازة قرّبت، وأكيد يبيلها بلايستيشن 🎮
3 أجهزة بلايستيشن موزّعة على 3 فائزين 🤩
كل اللي عليك تكتب في التعليقات هاشتاق #مصرف_الراجحي مع قلب أزرق 💙، وفالك الفوووز 😎
لا تنسى 👇
➕ تتابعنا
🔁 ريبوست
👍🏻 لايك
الشروط والأحكام: arb.sa/pEgOMuF
ayead retweeted
Replying to @AABO_Nawaf
مع كامل الاحترام ،، هذا ليس ترند و لا يعتد به .
ما يعتد به هو ترند يلامس القيعان أو قناة أو محور قناة أو منطقة أفقية حصل فيها تذبذب سابق سواء كان صعوداً أو هبوطاً .
#عبدالعزيز_العبدالعزيز_الرشيد
رحم الله عبدالعزيز الرشيد وغفر له واسكنه فسيح جناته
يا راحلٍ خلّيت في القلب حسرة
وخليت عقبك من الأسى ألف آه
4
296
مبروووووك للأخضر 🤩💚
وبهالمناسبة السعيدة بنسحب عشوائيًا على 2,000,000 نقطة #مكافأة موزّعة على 10 فائزين، كل اللي عليك تكتب تهنئتك للمنتخب في التعليقات مع هاشتاق #مكافأة 😎💙
ولا تنسى 👇
✅ تتابعنا
🔁 ريبوست
👍 لايك
الشروط والأحكام: arb.sa/pEgOMuF
أنصح جدا بهذا المنتج لحالات القلق و الإكتئاب كمساعد للعلاج الدوائي و السلوكي.. عشبة البابونج تساعد على الاسترخاء و تخفف التوتر
ayead retweeted
Replying to @AzizbagBag @fahad1398
جزاك الله خير على ماتقدم استاذ عبدالعزيز
كما نشكر الأستاذ فهد على جهوده
حفظ الله مملكتنا ومليكنا وولي عهده
#ذكرى_البيعة_الثانية_عشر #خادم_الحرمين_الشريفين
ayead retweeted
أحبتي الغاليين 💚
سوف يتم الليلة الإعلان عن أسماء المُهدى لهم بمناسبة #ذكري_البيعة_الثانيه_عشر
لمولاي
#خادم_الحرمين_الشريفين حفظه الله
وسوف يتواصل الغالي فهد@fahad1398 معكم على الخاص
علماً بإن المُهدى لهم لم يسبق لهم الحصول على جوال 17 برو
نلقاكم في اليوم الوطني بإذن الله.
مع إهداءات 50 جوال
-
يسبقها مساحه الجمعة القادمة
سوف تتضمن سداد 30 فاتورة كهرباء عبر الحساب الرسمي للشركة فقط بإذن الله.
محبتي
🇸🇦💚🇸🇦
ayead retweeted
ليست الغاية أن تكون قارئاً نهماً ، أو تاجراً حاذقاً، أو صاحب منصب ومكانة .. هذه وسائل وأسباب، وليست مقاصد وغايات.
الغاية أن تكون موحداً عابداً، ذاكراً مستغفراً، فتذكر الله كثيراً كل يوم، وتستغفر الله كثيراً كل يوم.
﴿يَا أَيُّهَا الَّذِينَ آمَنُوا اذْكُرُوا اللَّهَ ذِكْرًا كَثِيرًا ﴾
﴿وَاذكُر رَبكَ كَثيرًا﴾.
﴿وَالذَّاكِرِينَ اللهَ كَثِيرًا وَالذَّاكِرَاتِ﴾.
وفي الحديث: "سبق المُفَرِّدون ..الذاكرون الله كثيرا والذاكرات".
سبحان الله وبحمده ( ١٠٠ مرة).
أستغفر الله وأتوب إليه (١٠٠ مرة).
ومن زاد فنور على نور .
ayead retweeted
أختي المسلمة
إذا وجدتِ مثل هذه النصائح فقولي لقائلها:
أخ عبدالرحمن اللاحم @allahimAB
احتفظ بنصائحك لبناتك، فنحن بنات رجال كرام أحسنوا تربيتنا، وعلمونا اتخاذ قراراتنا المناسبة، ونعرف مصلحتنا سواء توظفنا أو لم نتوظف.
ayead retweeted
🛑🛑 مهرجان رسيس 🛑🛑
فلة سكنية في مدينة الرياض 🏠
و 4 سيارات بي إم دبليو 2026 🚙
هدية من رسيس بدون شروط أو قيود 🎁
المسابقة مصرحة برقم : 13619
تحت إشراف الغرفة التجارية ووزارة التجارة
#فلة_وسيارات_هدايا_رسيس
#رسيس_قول_وفعل
#اليوم_الوطني
ayead retweeted
بعد أول أسبوع دراسة كيف الأوضاع معكم 👀📚؟
بنوزّع 3 سماعات AirPods على 3 فائزين بشكل عشوائي من التعليقات 👇🏼
لا تنسى تتابعنا مع ريبوست 🔁
السحب يوم الأحد 📅
ayead retweeted
I'm a cardiologist. Today the FDA approved something I've been waiting two decades for: the first oral PCSK9 inhibitor in history. A once-daily pill — Lipfendra (enlicitide), from Merck — that lowers LDL as powerfully as the injections we've relied on.
This is one of those days that quietly changes the trajectory of the disease that kills more people than anything else on earth. Let me tell you exactly why — and who should act on it this week.
Start with the biology, because it's elegant.
Your liver cells are covered in LDL receptors — molecular catcher's mitts that grab "bad" cholesterol out of your blood and pull it in for disposal. The more receptors you have working, the lower your LDL. But your body makes a protein called PCSK9 whose entire job is to find those receptors and drag them to the incinerator before they can be reused. PCSK9 is the saboteur.
Block PCSK9, and the receptors survive. They get recycled back to the surface. They keep clearing LDL, over and over. Cholesterol plummets.
It is one of the most powerful mechanisms we have ever discovered in cardiology. And until today, you could only access it through a needle.
That needle was a bigger problem than most people realize. The injectables — Repatha, Praluent — are phenomenal drugs. But needle aversion, injection-site reactions, pharmacy logistics, and cost meant that millions of patients who desperately needed them simply said no. I have watched patients stay at heart-attack-level cholesterol for years because they wouldn't inject. The barrier was never the science. It was human.
Now the trial data — from a program spanning over 19,000 participants — and it's genuinely impressive.
Roughly 60% LDL reduction. A placebo-adjusted 56% in the main lipids trial, 59% in patients with inherited high cholesterol. On top of statins. That matches the injectable class in a daily tablet.
But here's the detail that made me sit up as a cardiologist — the part most coverage is burying: enlicitide also significantly lowered ApoB and Lp(a).
If you follow me, you know why that matters. Lp(a) is the genetic, inherited cholesterol particle that roughly one in five people carry at dangerous levels — the one that triples heart attack risk and that diet, exercise, and even statins barely touch. We've had almost nothing oral that moves it. A daily pill that lowers LDL, ApoB, AND Lp(a) simultaneously is a genuinely meaningful expansion of what we can do.
Who should pay attention today:
Anyone above their LDL goal despite maximum statins or ezetimibe. The roughly 9.8 million high-risk Americans still not at target.
Anyone with familial hypercholesterolemia — the genetic condition that loads dangerously high LDL from birth and causes heart attacks in the 40s and 50s. These patients have avoided the injectables for years.
Statin-intolerant patients who need powerful additional lowering.
Anyone who's had a heart attack or stroke and needs to drive LDL far lower than a statin alone can manage.
The price is notable too: about $315 a month, meaningfully below the injectables — though it'll still require insurance prior authorization, and formulary placement isn't set yet, so access won't be instant.
Now the honest caveats, because I'm a physician, not a hype man:
This approval is based on LDL lowering, not yet on proven outcomes. The big cardiovascular outcomes trial — CORALreef Outcomes, over 14,500 patients — is still running. We expect the heart-attack reduction to follow the LDL drop, because the link between lower LDL and fewer events is one of the most rock-solid relationships in all of medicine. But the definitive proof isn't in yet, and I'll tell you that honestly.
And a pill isn't automatically right for everyone. Some patients love a shot they take twice a month and never think about again. This is a powerful new tool, not a mandate.
But make no mistake about the size of this.
For twenty years I've told patients that LDL is one of the most important numbers they will ever own — and that for the right person, lower is better, and lower earlier is better still. Today the tool to get there stopped requiring a needle.
The medicine to protect your heart just got radically easier to take. And easier medicine is medicine people actually use.
If you're on a statin and still not at goal — or high cholesterol runs in your family and you've been dodging the shots — this is the week to call your doctor and ask one question:
"Is the new oral PCSK9 inhibitor right for me?"
The needle was the wall. Today the wall came down.
Know your numbers. The science to change them keeps winning.
ayead retweeted
(لا تترك الصلاة، ولا تأخرها عن وقتها، مهما بلغت ذنوبك)
"لايختلف المسلمون أن #ترك_الصلاة المفروضة عمداً من أعظم الذنوب، وأكبر الكبائر.
وأن إثم تارك الصلاة عند الله أعظم من إثم قتل النفس وأخذ الأموال، ومن إثم الزنا والسرقة وشرب الخمر.
وأنه متعرض لعقوبة الله وسخطه وخزيه في الدنيا والآخرة".
"وتارك الصلاة شر من السارق والزاني باتفاق العلماء .. والتي لا تصلي شر من الزانية والسارقة وشاربة الخمر".
-رسالة لتارك الصلاة:
صلِّ ولو في البيت أو المكتب أو السوق، فصلاتك وحدك خير ألف ألف مرة من ترك الصلاة بالكلية، أو تأخيرها عن وقتها.
ayead retweeted
I'm a cardiologist. I prescribe cholesterol-lowering drugs every single day. They save lives. That science is settled and I will never tell you otherwise.
But I'm going to say something that will make a lot of my colleagues uncomfortable — because someone needs to say it, and your doctor probably won't.
Too many physicians make you feel crazy when you bring up statin side effects.
You walk into your appointment and say "my muscles ache constantly" — and you're told it's in your head. You say "I'm exhausted all the time" — and you're told it's your age. You say "my sex drive disappeared" — and you get an awkward silence followed by a subject change. You say "I don't feel like myself anymore" — and you're told the benefits outweigh the risks, take the pill, stop reading the internet.
I've watched it happen in my own field for twenty years. The conversation gets shut down. The patient gets dismissed. And then they do the one thing we should be most afraid of — they stop the medication entirely, without telling us, and lose the cardiovascular protection that's keeping them alive.
That is the real cost of not being honest. Not the side effects themselves — the silence that drives patients away from treatment.
In my practice, I see statin-related complications in at least 25% of my patients. Muscle pain. Fatigue that doesn't resolve with sleep. Reduced sexual drive. Brain fog. Cramping. Joint stiffness. Weakness that makes exercise — the very thing we tell them to do — feel impossible.
Some of these improve with CoQ10 supplementation and optimizing vitamin D. Many do not.
I wrote about the diabetes risk of statins in a New York Times op-ed in 2012. The backlash from the cardiology establishment was immediate. I was told I was undermining trust in a life-saving drug class. Fourteen years later, every major guideline acknowledges the risk I warned about. It's in the prescribing information. The physicians who attacked me for saying it now teach it to their residents.
The truth doesn't care about professional comfort. It never has.
Now a paper published this week in Science Advances has finally explained the mechanism behind statin myopathy — and the finding validates what millions of patients have been telling their doctors for years.
Researchers discovered that statins activate the NLRP3 inflammasome in muscle cells — triggering an inflammatory cascade that causes muscle cell death, activates atrophy pathways, and disrupts muscle metabolism. This is entirely independent of the drug's cholesterol-lowering effect.
The muscle damage isn't caused by lowering cholesterol. It's caused by a completely separate pharmacological action through a different pathway.
The critical implication: the side effect can potentially be separated from the benefit.
Blocking NLRP3 or restoring isoprenoids prevented muscle cell death without interfering with cholesterol reduction. Future therapies could preserve the cardiovascular protection while eliminating the muscle toxicity.
Even more striking — the researchers found that background systemic inflammation significantly lowered the statin dose needed to trigger muscle damage. Patients with chronic inflammation, gut dysbiosis, or metabolic syndrome may be experiencing myopathy at doses their doctors consider "too low to cause problems." They're not imagining it. Their inflammatory state is priming the pathway.
The muscle pain was never in their heads. It was in their NLRP3 inflammasome. And we finally have the molecular proof.
Here's what I actually do in my practice — because I refuse to choose between protecting the heart and respecting the patient.
Whenever possible, I avoid statins as my first-line approach for eligible patients by using alternatives that lower LDL through entirely different mechanisms with no muscle toxicity:
PCSK9 inhibitors — Repatha and Praluent. Injections every 2-4 weeks that dramatically lower LDL without touching muscle tissue. No myopathy. No fatigue. No brain fog. For patients who can access them, these are transformative.
Inclisiran — Leqvio. An siRNA injection I administer twice a year in my office. It silences the PCSK9 gene in the liver. Two shots a year. LDL drops roughly 50%. No muscle side effects. No daily pills. Now approved as first-line monotherapy. This is the future of lipid management and I use it aggressively.
When statins ARE clinically necessary — and sometimes they are, especially post-heart attack or in combination therapy — I choose hydrophilic statins like rosuvastatin or pravastatin. These do not easily cross the blood-brain barrier. The cognitive complaints — the fog, the memory issues, the feeling of "not being yourself" — are substantially less common with these formulations because the drug stays out of the central nervous system.
I never prescribe a statin without CoQ10. 100-300mg daily. Statins deplete the cellular energy molecule your muscles and heart depend on. Replenishing it reduces muscle symptoms in many patients. It should be standard practice. The fact that it isn't is a failure of our field.
I check vitamin D and optimize it aggressively. Low vitamin D — which is epidemic — worsens muscle symptoms independently and compounds whatever the statin is doing. Target 50-80 ng/mL, not the bare minimum of 30.
Bempedoic acid — Nexletol — for patients who can't tolerate any statin. Works upstream in the cholesterol pathway and is not active in muscle tissue. Specifically designed to avoid myopathy.
Ezetimibe added to a lower statin dose. Cut the statin intensity, add ezetimibe to maintain the LDL reduction, and halve the muscle exposure.
There is no excuse in 2026 for telling a patient "just deal with the muscle pain." The toolbox is deep. The alternatives exist. The only barrier is a physician's willingness to listen and adapt.
I want to speak directly to every patient who has been dismissed.
Your muscle pain is real. Your fatigue is real. Your cognitive changes are real. Your loss of drive — in every sense of the word — is real. A paper in Science Advances just proved the mechanism. You were never crazy. You were experiencing a documented inflammatory response in your muscle tissue that your doctor didn't have the science to explain — until this week.
And I want to speak directly to my colleagues.
We have to be honest. Not just about the benefits — which are enormous and undeniable — but about the side effects, the mechanism, and the alternatives. Patients who feel heard stay on treatment. Patients who feel dismissed stop their medications in silence — and die from the heart attacks we could have prevented if we'd simply been willing to have an honest conversation and switch the approach.
The cardiologist who tells you statins are flawless is not protecting you. The wellness influencer who tells you statins are poison is not protecting you either. The truth lives in the middle — where it always has.
Statins save lives. The side effects are real. The mechanism is now proven. The alternatives exist. And you deserve a doctor who holds all four of those truths at the same time.
Both things can be true. They always could.
Now we have the science to prove it.























